Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 ...

September 16, 2024

Alphamab Oncology presented JSKN003's clinical data at ESMO Congress 2024, showing promising efficacy in platinum-resistant ovarian cancer and advanced HER2-positive solid tumors, with favorable safety profiles.

Related Clinical Trials

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Reference News

prnewswire.com

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 ...